   |
|
Location: Moscow, Russia
Reports to: Vice President R&D
Duties and Responsibilities:
This position will be responsible for developing the analytical methods, both chemical and physical, for Selecta's proprietary targeted nanoparticles. This will include transfer of knowhow from Selecta Biosciences (Boston, MA, USA) as well as the creation of new methods, application for R&D purposes and development to a stage suitable for pre-clinical testing and clinical trials. The successful candidate will develop a wide range of analytical methods and sample preparations for complex polymeric particles containing one or more active entities. This position will require hands-on work in setting up the lab, developing methods and running assays in support of Selecta's product development as well as building and leading a highly functional and talented team. The successful candidate will also be able to work with people with diverse backgrounds and abilities for the purpose of solving complex chemical and biological problems for the development of products. Excellent written and oral communication skills in English and Russian are required as is the demonstrated ability to lead cross functional teams. Travel to the United States for training and other research related functions at Selecta's USA facilities will also be part of the role.
Education Requirements: Ph.D. in Chemistry or related discipline
Experience: Minimum of 8 years experience in pharmaceutical analytical development. Experience with polymeric particulate systems a plus.
About Selecta:
Selecta Biosciences, Inc. is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications. Selecta's proprietary Synthetic Vaccine Particle (SVP™) platform creates a new paradigm in vaccine development, enabling completely new therapeutic applications while offering the potential of improved efficacy and safety profiles. Selecta's fully synthetic engineering of novel vaccines offers a number of compelling benefits, including flexible modular vaccine design and accelerated development timelines using robust manufacturing processes. Selecta's SVP™ platform technology is flexible to enable diverse vaccines and the company has created antigen-specific targeted Synthetic Vaccine Particles (tSVP™) and antigen-specific targeted tolerogenic Synthetic Vaccine Particles (t2SVP™).
Selecta was founded based on the advanced nanoparticle technology from the laboratories of two leaders in the field of targeted nanotechnology, Professor Robert Langer, Institute Professor of the Massachusetts Institute of Technology (MIT) and Professor Omid Farokhzad of Harvard Medical School as well as immunology research of Professor Ulrich von Andrian at Harvard Medical School. Selecta Biosciences is based in Watertown, Massachusetts, USA. For more information, please visit www.selectabio.com.
About Selecta Russia:
Selecta Russia is a wholly-owned subsidiary of Selecta Biosciences, Inc.
The company mission is to build a robust pipeline of Synthetic Vaccine Particles (SVP™) vaccines for the global marketplace. Our activities in Russia support Selecta Biosciences' goals of expanding its vaccine portfolio and accelerating its clinical development, while recognizing the specific requirements of Russian patients. Selecta Russia R&D programs are developed in close coordination with Selecta in Boston and include prophylactic and therapeutic vaccines in a wide range of therapeutic areas including infectious diseases, cancer, and addiction.
Please email your Resume/CV in English and Russian language to careers@selectabio.com.
NO PHONE CALLS OR AGENCIES PLEASE.
Selecta Biosciences, Inc. is an equal opportunity employer offering a competitive salary and benefits package
Please refer to Job Code CHEM3 when corresponding about this position.